FDA Panel Sees Role For PK/PD Modeling In Revising Antibiotic “Breakpoints”
Executive Summary
In certain circumstances it may be appropriate to change the criteria for determining when a pathogen is susceptible to a drug and recommended doses for systemic antibacterials absent clinical outcomes data, Anti-Infective Drugs Advisory Committee says.